Volume 139, Issue 2, Pages (August 2010)

Slides:

Advertisements

Similar presentations

Mentore Ribolsi, Richard H

Advertisements

Gastrin in Gastrointestinal Diseases

Volume 136, Issue 5, Pages (May 2009)

Investigation of Outbreak of Infections Caused by Salmonella Saintpaul

Complications of Proton Pump Inhibitor Therapy

Huiqin He, Zhinong Jiang, Leimin Sun Gastroenterology

Pancreatic Mass in a Patient With an Increased Serum Level of IgG4

Christoph Lübbert, Babett Holler Gastroenterology

Community Colonoscopy: A Gordian Knot?

Covering the Cover Gastroenterology

Volume 145, Issue 4, Pages (October 2013)

Genetics and Genomics in the Practice of Medicine

Persistent Reflux Symptoms in the Proton Pump Inhibitor Era: The Changing Face of Gastroesophageal Reflux Disease Evan S. Dellon, Nicholas J. Shaheen

Volume 144, Issue 4, Pages e17-e18 (April 2013)

Volume 136, Issue 4, Pages (April 2009)

Ira J. Fox, Stephen C. Strom Gastroenterology

Volume 141, Issue 2, Pages (August 2011)

Volume 132, Issue 3, Pages (March 2007)

American Gastroenterological Association Institute Technical Review on the Management of Gastroesophageal Reflux Disease Peter J. Kahrilas, Nicholas.

Investigation of Outbreak of Infections Caused by Salmonella Saintpaul

Covering the Cover Gastroenterology

Intragastric pH With Oral vs Intravenous Bolus Plus Infusion Proton-Pump Inhibitor Therapy in Patients With Bleeding Ulcers Loren Laine, Abbid Shah,

Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy Christina Reimer, Bo Søndergaard, Linda.

Clinical Challenges and Images in GI

Persistent Reflux Symptoms in the Proton Pump Inhibitor Era: The Changing Face of Gastroesophageal Reflux Disease Evan S. Dellon, Nicholas J. Shaheen

Serhat Bor, Gul Kitapcioglu, Peter Dettmar, Tim Baxter

Volume 150, Issue 4, Pages (April 2016)

Management of Patients With Functional Heartburn

A Historical Perspective on Clinical Advances in Pancreatic Diseases

Volume 150, Issue 4, Pages (April 2016)

Yutaka Tomizawa, Lei Zhao, Leslie W. Yang Gastroenterology

Kenneth E.L. McColl, Derek Gillen Gastroenterology

Mentore Ribolsi, Richard H

Maintenance of Heartburn Relief After Step-Down From Twice-Daily Proton Pump Inhibitor to Once-Daily Dexlansoprazole Modified Release Ronnie Fass, John.

Volume 133, Issue 6, Pages (December 2007)

Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease David A. Johnson, M.Brian Fennerty

Volume 136, Issue 5, Pages (May 2009)

Many Patients Continue Using Proton Pump Inhibitors After Negative Results From Tests for Reflux Disease Andrew J. Gawron, Jami Rothe, Angela J. Fought,

Increased Prandial Air Swallowing and Postprandial Gas-Liquid Reflux Among Patients Refractory to Proton Pump Inhibitor Therapy Ivana Bravi, Philip Woodland,

Volume 124, Issue 4, Pages (April 2003)

Rafael Esteban, Maria Buti Gastroenterology

A Selection of the Best AGA Abstracts of DDW 2017

Peter Bytzer Clinical Gastroenterology and Hepatology

Volume 133, Issue 2, Pages (August 2007)

Ashwin N. Ananthakrishnan, David Lieberman Gastroenterology

Volume 154, Issue 4, Pages (March 2018)

Volume 148, Issue 3, Pages (March 2015)

Systematic Review: Patterns of Proton Pump Inhibitor Use and Adherence in Gastroesophageal Reflux Disease A. Pali S. Hungin, Catherine Hill, Michael.

Volume 149, Issue 6, Pages (November 2015)

Volume 150, Issue 7, Pages (June 2016)

The Rise and Fall (and Rise?) of Endoscopic Anti-Reflux Procedures

The Utility of Intraluminal Impedance in Patients With Gastroesophageal Reflux Disease–Like Symptoms But Normal Endoscopy and 24-Hour pH Testing Michael.

The Dawning of a New Editorial Board for Gastroenterology

Volume 151, Issue 4, Pages (October 2016)

Volume 156, Issue 1, Pages 7-10 (January 2019)

Issue Highlights Clinical Gastroenterology and Hepatology

Volume 127, Issue 5, Pages (November 2004)

Volume 156, Issue 5, Pages (April 2019)

Changing of the Guards: 2011–2016 Gastroenterology Team

Michelle Maria Pietzak Gastroenterology

Volume 139, Issue 2, Pages (August 2010)

Volume 155, Issue 6, Pages (December 2018)

Volume 139, Issue 6, Pages e1 (December 2010)

Capsule Endoscopy for Refractory Iron Deficiency Anemia in Crohn’s Disease: Captivating Pathology, Hybrid Therapy Long Le, Brian M. Fung, James H. Tabibian

Volume 136, Issue 3, Pages (March 2009)

End-Stage Liver Disease in 2008: Finally a Glass Half Full

Volume 153, Issue 3, Pages e2 (September 2017)

Electronic Clinical Challenges and Images in GI

The Future of Endoscopic Retrograde Cholangiopancreatography

Abnormal Gastrointestinal Imaging in a Patient With Dyspepsia

Presentation transcript:

Volume 139, Issue 2, Pages 409-417 (August 2010) Effects of Lesogaberan on Reflux and Lower Esophageal Sphincter Function in Patients With Gastroesophageal Reflux Disease Guy E. Boeckxstaens, Hanneke Beaumont, Veerle Mertens, Hans Denison, Magnus Ruth, John Adler, Debra G. Silberg, Daniel Sifrim Gastroenterology Volume 139, Issue 2, Pages 409-417 (August 2010) DOI: 10.1053/j.gastro.2010.04.051 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Study design showing (A) randomization schedule and visits and (B) schedule of dosing, standardized meals, and pharmacodynamic and symptom assessments. Patients received lesogaberan or placebo in addition to their current proton pump inhibitor therapy. Gastroenterology 2010 139, 409-417DOI: (10.1053/j.gastro.2010.04.051) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Number of TLESRs with lesogaberan or placebo (A) for individual patients 0–3 hours after the standardized meal consumed 1 hour after the third dose and (B) hourly geometric means over the 4 hours after the third dose. Error bars show 95% CIs. Gastroenterology 2010 139, 409-417DOI: (10.1053/j.gastro.2010.04.051) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 Mean LES pressure with lesogaberan and placebo during the stationary assessment 4 hours after the third treatment dose. Error bars show upper or lower extent of 95% CIs. Gastroenterology 2010 139, 409-417DOI: (10.1053/j.gastro.2010.04.051) Copyright © 2010 AGA Institute Terms and Conditions

Figure 4 Mean number of reflux episodes with lesogaberan and placebo (A) during the stationary assessment 0–3 hours after the meal consumed 1 hour after the third dose and (B) during the ambulatory assessment 0–24 hours after the first dose. (C) Mean number of pure liquid, mixed gas/liquid, and pure gas reflux episodes with lesogaberan and placebo, during the stationary assessment 0–4 hours after the third treatment dose and during the ambulatory assessment 0–24 hours after the first dose. Error bars show 95% CIs. Gastroenterology 2010 139, 409-417DOI: (10.1053/j.gastro.2010.04.051) Copyright © 2010 AGA Institute Terms and Conditions